top of page

SABINA
OFFICIAL TITLE: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN

PIK3CA/PTEN
altered
metaplastic
breast cancer
II
28
8
Spain
Recruitment
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE FOR COHORT A IS TO ASSESS THE EFFICACY OF THE COMBINATION OF MEN1611 WITH ERIBULIN AS DETERMINED BY CLINICAL BENEFIT RATE IN UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HR-KNOWN/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED METAPLASTIC BREAST CARCINOMA. THE PRIMARY OBJECTIVE FOR COHORT B IS TO ASSESS THE EFFICACY OF MEN1611 AS MONOTHERAPY AS DETERMINED BY THE OBJECTIVE RESPONSE RATE AT 6 WEEKS.
SABINA AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TRIAL RESUME


SABINA SITES


SPAIN
Instituto Valenciano de Oncología

SPAIN
Hospital Universitario Virgen del Rocío

SPAIN
Onkologikoa

SPAIN
Hospital Universitario de Torrejón

SPAIN
Hospital Universitario Clínico San Cecilio de Granada

SPAIN
Institut Català d’ Oncologia L’Hospitalet

SPAIN
Hospital Universitario de Torrejón

SPAIN
Hospital Universitari Vall D'Hebron
bottom of page